{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:11:52Z","timestamp":1649157112393},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00347-012-2586-z","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T12:47:09Z","timestamp":1339678029000},"page":"563-567","source":"Crossref","is-referenced-by-count":4,"title":["Anmerkungen zur Pathogenese des Morbus Beh\u00e7et"],"prefix":"10.1007","volume":"109","author":[{"given":"U.","family":"Pleyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hazirolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"St\u00fcbiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,16]]},"reference":[{"key":"2586_CR1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2230.2006.02157.x","volume":"3","author":"Aki","year":"2006","unstructured":"Aki T, Karincaoglu Y, Seyhan M, Batcioglu K (2006) Serum substance P and calcitonin gene-related peptide levels in Beh\u00e7et\u2019s disease and their association with disease activity. Clin Exp Dermatol 3:583\u2013587","journal-title":"Clin Exp Dermatol"},{"key":"2586_CR2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/ard.2004.032060","volume":"64","author":"Alexander","year":"2005","unstructured":"Alexander T, Klotz O, Feist E et al (2005) Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1receptor antagonist. Ann Rheum Dis 64:1245\u20131246","journal-title":"Ann Rheum Dis"},{"key":"2586_CR3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","volume":"13","author":"Amadi-Obi","year":"2007","unstructured":"Amadi-Obi A, Yu CR, Liu X et al (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1. Nat Med 13:711\u2013718","journal-title":"Nat Med"},{"key":"2586_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000077332","volume":"36","author":"Aydin","year":"2004","unstructured":"Aydin E, S\u00f6g\u00fct S, Ozyurt H et al (2004) Comparison of serum nitric oxide, malondialdehyde levels, and antioxidant enzyme activities in Beh\u00e7et\u2019s disease with and without ocular disease. Ophthalmic Res 36:177\u2013182","journal-title":"Ophthalmic Res"},{"key":"2586_CR5","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/art.20334","volume":"50","author":"Ben","year":"2004","unstructured":"Ben Ahmed M, Houman H, Miled M et al (2004) Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Beh\u00e7et\u2019s disease. Arthritis Rheum 50:2291\u20132295","journal-title":"Arthritis Rheum"},{"key":"2586_CR6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","volume":"149","author":"Botsios","year":"2008","unstructured":"Botsios C, Sfriso P, Furlan A et al (2008) Resistant Beh\u00e7et disease responsive to anakinra. Ann Intern Med 149:284\u2013286","journal-title":"Ann Intern Med"},{"key":"2586_CR7","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.1780391216","volume":"39","author":"Calguneri","year":"1996","unstructured":"Calguneri M, Kiraz S, Ertenli I et al (1996) The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet\u2019s disease. A randomized clinical trial. Arthritis Rheum 39:2062\u20132065","journal-title":"Arthritis Rheum"},{"key":"2586_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"Dinarello","year":"2009","unstructured":"Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519\u2013550","journal-title":"Annu Rev Immunol"},{"key":"2586_CR9","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.60.11.996","volume":"60","author":"Direskeneli","year":"2001","unstructured":"Direskeneli H (2001) Beh\u00e7et\u2019s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60:996\u20131002","journal-title":"Ann Rheum Dis"},{"key":"2586_CR10","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/rheumatology\/kel329","volume":"45","author":"Direskeneli","year":"2006","unstructured":"Direskeneli H (2006) Autoimmunity vs autoinflammation in Behcet\u2019s disease: Do we oversimplify a complex disorder? Rheumatology 45:1461\u20131465","journal-title":"Rheumatology"},{"key":"2586_CR11","first-page":"826","volume":"26","author":"Ek\u015fioglu-Demiralp","year":"1999","unstructured":"Ek\u015fioglu-Demiralp E, Kibaroglu A, Direskeneli H et al (1999) Phenotypic characteristics of B cells in Beh\u00e7et\u2019s disease: increased activity in B cell subsets. J Rheumatol 26:826\u2013832","journal-title":"J Rheumatol"},{"key":"2586_CR12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s100510170348","volume":"19","author":"Ertenli","year":"2001","unstructured":"Ertenli I, Kiraz S, Calguneri M et al (2001) Synovial fluid cytokine levels in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 19:37\u201341","journal-title":"Clin Exp Rheumatol"},{"key":"2586_CR13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00393-009-0488-5","volume":"68","author":"Gadola","year":"2009","unstructured":"Gadola SD (2009) Interleukin-1 cytokines, inflammasomes, NOD-signalosomes and autoinflammation. Z Rheumatol 68:712\u2013719","journal-title":"Z Rheumatol"},{"key":"2586_CR14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","volume":"128","author":"Geri","year":"2011","unstructured":"Geri G, Terrier B, Rosenzwajg M et al (2011) Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease. J Allergy Clin Immunol 128:655\u2013664","journal-title":"J Allergy Clin Immunol"},{"key":"2586_CR15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11882-008-0047-1","volume":"8","author":"Glaser","year":"2008","unstructured":"Glaser RL, Goldbach-Mansky R (2008) The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies. Curr Allergy Asthma Rep 8:288\u2013298","journal-title":"Curr Allergy Asthma Rep"},{"key":"2586_CR16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/rheumatology\/40.6.668","volume":"40","author":"G\u00fcl","year":"2001","unstructured":"G\u00fcl A, Uyar FA, Inanc M et al (2001) Lack of association of HLA-B*51 with a severe disease course in Behcet\u2019s disease. Rheumatology 40:668\u2013672","journal-title":"Rheumatology"},{"key":"2586_CR17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-4632.2004.02184.x","volume":"44","author":"G\u00fcr-Toy","year":"2005","unstructured":"G\u00fcr-Toy G, Lenk N, Yalcin B et al (2005) Serum interleukin-8 as a serologic marker of activity in Beh\u00e7et\u2019s disease. Int J Dermatol 44:657\u2013660","journal-title":"Int J Dermatol"},{"key":"2586_CR18","first-page":"49","volume":"23","author":"Hamzaoui","year":"2005","unstructured":"Hamzaoui K, Hamzaoui A, Bouajina L, Houman H (2005) Circulating soluble CD28 in patients with Beh\u00e7et\u2019s disease: relationship to clinical manifestations. Clin Exp Rheumatol 23(4 Suppl 38):49\u201352","journal-title":"Clin Exp Rheumatol"},{"key":"2586_CR19","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","volume":"348","author":"Hawkins","year":"2003","unstructured":"Hawkins PN, Lachmann HJ, McDermott MF (2003) Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348:2583\u20132584","journal-title":"N Engl J Med"},{"key":"2586_CR20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2249.1998.00572.x","volume":"112","author":"Hirohata","year":"1998","unstructured":"Hirohata S, Hashimoto T (1998) Abnormal T cell responses to bacterial superantigens in Beh\u00e7et\u2019s disease (BD). Clin Exp Immunol 112:317\u2013324","journal-title":"Clin Exp Immunol"},{"key":"2586_CR21","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","volume":"364","author":"Hoffman","year":"2004","unstructured":"Hoffman HM, Rosengren S, Boyle DL et al (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779\u20131785","journal-title":"Lancet"},{"key":"2586_CR22","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2444::AID-IMMU2444>3.0.CO;2-N","volume":"28","author":"Hu","year":"1998","unstructured":"Hu W, Hasan A, Wilson A et al (1998) Experimental mucosal induction of uveitis with the 60-kDa heat shock protein-derived peptide 336\u2013351. Eur J Immunol 28:2444\u20132455","journal-title":"Eur J Immunol"},{"key":"2586_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000313546","volume":"45","author":"Kim","year":"2010","unstructured":"Kim TW, Chung H, Yu HG (2010) Chemokine expression of intraocular lymphocytes in patients with Beh\u00e7et uveitis. Ophthalmic Res 45:5\u201314","journal-title":"Ophthalmic Res"},{"key":"2586_CR24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nature04515","volume":"440","author":"Mariathasan","year":"2006","unstructured":"Mariathasan S, Weiss DS, Newton K et al (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228\u2013232","journal-title":"Nature"},{"key":"2586_CR25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"Martinon","year":"2009","unstructured":"Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229\u2013265","journal-title":"Annu Rev Immunol"},{"key":"2586_CR26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"Mizuki","year":"2010","unstructured":"Mizuki N, Meguro A, Ota M et al (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et\u2019s disease susceptibility loci. Nat Genet 42:703\u2013706","journal-title":"Nat Genet"},{"key":"2586_CR27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2249.2004.02520.x","volume":"137","author":"Stanford","year":"2004","unstructured":"Stanford M, Whittall T, Bergmeier LA et al (2004) Oral tolerization with peptide 336\u2013351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet\u2019s disease. Clin Exp Immunol 137:201\u2013208","journal-title":"Clin Exp Immunol"},{"key":"2586_CR28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1034\/j.1399-0039.1999.540307.x","volume":"54","author":"Verity","year":"1999","unstructured":"Verity DH, Wallace GR, Vaughan RW et al (1999b) HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet\u2019s disease. Tissue Antigens 54:264\u2013272","journal-title":"Tissue Antigens"},{"key":"2586_CR29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ajo.2009.09.018","volume":"149","author":"Zamecki","year":"2010","unstructured":"Zamecki KJ, Jabs DA (2010) HLA typing in uveitis: use and misuse. Am J Ophthalmol 149:189\u2013193","journal-title":"Am J Ophthalmol"},{"key":"2586_CR30","first-page":"81","volume":"44","author":"Zouboulis","year":"1993","unstructured":"Zouboulis CC, Buttner P, Djawari D et al (1993) The HLA pattern in Adamantiades-Behcet\u2019s disease in Germany. Association of occurrence, clinical symptoms and follow-up in 39 patients. Hautarzt 44:81\u201385","journal-title":"Hautarzt"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-012-2586-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-012-2586-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-012-2586-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:51:48Z","timestamp":1559051508000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-012-2586-z"}},"subtitle":["Ein Schl\u00fcssel zum Verst\u00e4ndnis neuer Therapien?"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["2586"],"URL":"https:\/\/doi.org\/10.1007\/s00347-012-2586-z","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}